Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L-PLUS 2)

Published on Oct 1, 2019in Hepatology14.679
· DOI :10.1002/HEP.30561
M Peck-Radosavljevic6
Estimated H-index: 6
(MIT: Massachusetts Institute of Technology),
Markus Peck-Radosavljevic1
Estimated H-index: 1
(MIT: Massachusetts Institute of Technology)
+ 16 AuthorsNezam H. Afdhal92
Estimated H-index: 92
(BIDMC: Beth Israel Deaconess Medical Center)
: Thrombocytopenia may be associated with increased bleeding risk impacting timing and outcome of invasive procedures in patients with chronic liver disease (CLD). Lusutrombopag, a small-molecule, thrombopoietin (TPO) receptor agonist, was evaluated as a treatment to raise platelet counts (PCs) in patients with thrombocytopenia and CLD undergoing invasive procedures. L-PLUS 2 was a global, phase 3, randomized, double-blind, placebo-controlled study. Adults with CLD and baseline PCs < 50 × 109 /L were randomized to receive once-daily lusutrombopag 3 mg or placebo ≤ 7 days before an invasive procedure scheduled 2-7 days after the last dose. The primary endpoint was avoidance of preprocedure platelet transfusion and avoidance of rescue therapy for bleeding. A key secondary endpoint was number of days PCs were ≥ 50 × 109 /L throughout the study. Safety analysis was performed on patients who received at least one dose of study drug. This study occurred between June 15, 2015, and April 19, 2017, with a total of 215 randomized patients (lusutrombopag, 108; placebo, 107); 64.8% (70/108) of patients in the lusutrombopag group versus 29.0% (31/107) in the placebo group met the primary endpoint (P < 0.0001; difference of proportion 95% confidence interval [CI], 36.7 [24.9, 48.5]). The median duration of PCs ≥ 50 × 109 /L was 19.2 days with lusutrombopag (without platelet transfusion) compared with 0.0 in the placebo group (with platelet transfusion) (P = 0.0001). Most adverse events were mild or moderate in severity, and rates were similar in the lusutrombopag and placebo groups (47.7% and 48.6%, respectively). Conclusion: Lusutrombopag was superior to placebo for reducing the need for platelet transfusions and achieved durable PC response in patients with thrombocytopenia and CLD undergoing invasive procedures, with a safety profile similar to placebo.
📖 Papers frequently viewed together
76 Citations
208 Citations
#1Hisashi Hidaka (Kitasato University)H-Index: 19
#2Masayuki KurosakiH-Index: 51
Last. Michio ImawariH-Index: 25
view all 20 authors...
Background & Aims Platelet transfusion is used to prevent hemorrhagic events in patients with thrombocytopenia undergoing invasive procedures, but there are many disadvantages. We evaluated the efficacy and safety of lusutrombopag in patients with chronic liver disease and thrombocytopenia undergoing invasive procedures. Methods We performed a double-blind, parallel-group, phase 3 study of 96 patients with chronic liver disease and thrombocytopenia (platelet counts below 50,000/μL) undergoing in...
46 CitationsSource
#1Ryosuke Tateishi (UTokyo: University of Tokyo)H-Index: 53
#2Masataka Seike (Oita University)H-Index: 24
Last. Michio ImawariH-Index: 25
view all 15 authors...
Background Thrombocytopenia represents an obstacle for invasive procedures in chronic liver disease (CLD) patients. We aimed to estimate the appropriate dose and evaluate the efficacy and safety of lusutrombopag for the treatment of thrombocytopenia before percutaneous liver radiofrequency ablation (RFA) for primary hepatic cancer in patients with CLD.
38 CitationsSource
#1Lorenzo Loffredo (Sapienza University of Rome)H-Index: 38
#2Francesco Violi (Sapienza University of Rome)H-Index: 86
Abstract Background Treatment of thrombocytopenia with thrombopoietin receptor agonists (TPORAs) seems to be associated with portal vein thrombosis (PVT) in patients with chronic liver disease (CLD). We performed a meta-analysis of the trials carried out in this clinical setting to assess if such association is detectable. Methods We performed a meta-analysis with studies that compared the effect of TPORAS vs placebo in patients with CLD and thrombocytopenia. Results Four studies, including 1953...
14 CitationsSource
#1Norah A. Terrault (UCSF: University of California, San Francisco)H-Index: 87
#2Yi-Cheng Chen (Memorial Hospital of South Bend)H-Index: 1
Last. Tarek HassaneinH-Index: 65
view all 8 authors...
Abstract Background & Aims Patients with thrombocytopenia and chronic liver disease (CLD) may require platelet transfusions before scheduled procedures to decrease risk of bleeding. We performed 2 randomized, placebo-controlled, phase 3 trials in patients with thrombocytopenia and CLD undergoing scheduled procedures to evaluate the safety and efficacy of avatrombopag in increasing platelet counts in this patient population Methods In the ADAPT-1 and ADAPT-2 studies, adults with thrombocytopenia ...
76 CitationsSource
#1Nicolas M. Intagliata (UVA: University of Virginia)H-Index: 15
#2Curtis K. Argo (UVA: University of Virginia)H-Index: 31
Last. Francesco Violi (Sapienza University of Rome)H-Index: 86
view all 6 authors...
73 CitationsSource
#1Filippo SchepisH-Index: 26
#2Laura TurcoH-Index: 11
Last. Erica VillaH-Index: 45
view all 4 authors...
Cirrhosis represents the end stage of chronic liver disease and its transition from a compensated to a decompensated status is mainly driven by portal hypertension and systemic inflammation. Although relevant modifications in the evaluation of the coagulative balance in cirrhosis across its natural history have occurred and alterations in routine indices of hemostasis have lost their role as indicators of the hemorrhagic risk of patients with liver cirrhosis, these are still perceived as prone t...
21 CitationsSource
#1Edoardo G. Giannini (UniGe: University of Genoa)H-Index: 57
#2Giorgia Bodini (UniGe: University of Genoa)H-Index: 18
Last. Elisa Marabotto (UniGe: University of Genoa)H-Index: 18
view all 4 authors...
1 CitationsSource
#1Stefania Basili (Sapienza University of Rome)H-Index: 55
#2Valeria Raparelli (Sapienza University of Rome)H-Index: 23
Last. Francesco VioliH-Index: 86
view all 13 authors...
Platelet Count Does Not Predict Bleeding in Cirrhotic Patients: Results from the PRO-LIVER Study
31 CitationsSource
Thrombocytopenia is a common haematological disorder in patients with chronic liver disease. It is multifactorial and severity of liver disease is the most influential factor. As a result of the increased risk of bleeding, thrombocytopenia may impact upon medical procedures, such as surgery or liver biopsy. The pathophysiology of thrombocytopenia in chronic liver disease has long been associated with the hypothesis of hypersplenism, where portal hypertension causes pooling and sequestration of a...
75 CitationsSource
#1G. NapolitanoH-Index: 12
#2A. IacobellisH-Index: 17
Last. Angelo AndriulliH-Index: 73
view all 11 authors...
Abstract Background In cirrhotics with low circulating platelets (PLT), restoration of normal cell counts has been traditionally recommended before invasive procedures. However, there is neither consensus on the PLT transfusion threshold nor evidence of its clinical efficacy. Patients In order to fill this gap of knowledge, we prospectively collected and analyzed data on circulating PLT counts [and International Normalized Ratio (INR)] values in a case series of 363 cirrhotics scheduled to under...
52 CitationsSource
Cited By56
#1Massimo PrimignaniH-Index: 20
#2Giulia TosettiH-Index: 8
Last. Armando TripodiH-Index: 28
view all 3 authors...
#1Junzhu Deng (CDUTCM: Chengdu University of Traditional Chinese Medicine)
#2Haiyang Hu (CDUTCM: Chengdu University of Traditional Chinese Medicine)
Last. Wenjun Zou (CDUTCM: Chengdu University of Traditional Chinese Medicine)H-Index: 7
view all 11 authors...
Thrombopoietin receptor agonists (TPO-RAs) play a crucial role in stimulating thrombopoiesis. However, conventional meta-analyses have shown inconsistent results regarding the efficacy of thrombopoietin receptor agonists. Therefore, we performed a network meta-analysis to assess the effects of five TPO-RAs via direct and indirect comparison. For this network meta-analysis, we considered randomized trials that included any of the following interventions: avatrombopag, lusutrombopag, eltrombopag, ...
#1Shreya Desai (RFUMS: Rosalind Franklin University of Medicine and Science)
#2Anita Subramanian (Campbell University)
Thrombocytopenia is a common hematologic complication seen in patients with chronic liver disease (CLD). The pathophysiology of thrombocytopenia in CLD is multifactorial, primarily stemming from platelet sequestration and decreased platelet production. This review focuses on the pathophysiology and current treatment options in the treatment of thrombocytopenia in chronic liver disease. While platelet transfusions are the gold standard of treatment, considerations ought to be given to CLD patient...
#1Hitoshi Yoshiji (Nara Medical University)H-Index: 1
#2Sumiko NagoshiH-Index: 16
Last. Masahito ShimizuH-Index: 57
view all 21 authors...
The first edition of the clinical practice guidelines for liver cirrhosis was published in 2010, and the second edition was published in 2015 by the Japanese Society of Gastroenterology (JSGE). The revised third edition was recently published in 2020. This version has become a joint guideline by the JSGE and the Japanese Society of Hepatology (JSH). In addition to the clinical questions (CQs), background questions (BQs) are new items for basic clinical knowledge, and future research questions (F...
#1Massimo PrimignaniH-Index: 20
#2Giulia TosettiH-Index: 8
Last. Armando TripodiH-Index: 68
view all 3 authors...
#2Sachie InoueH-Index: 1
Last. Ryosuke Tateishi (UTokyo: University of Tokyo)H-Index: 53
view all 6 authors...
Background and Aim Thrombocytopenia is a frequent hematological condition in chronic liver disease (CLD) patients increasing the risk of bleeding in patients undergoing invasive procedures. Without an alternative, clinical guidelines recommended the use of platelet transfusion (PT) prior to procedure to prevent this bleeding risk. Lusutrombopag (LUSU), an orally active, small-molecule thrombopoietin receptor agonist, was developed as an alternative to PT. The objective of this study was to evalu...
#1Jeffrey A. Gilreath (UofU: University of Utah)H-Index: 9
#2Mimi Lo (UCSF: University of California, San Francisco)
Last. Joseph Bubalo (APhA: American Pharmacists Association)
view all 3 authors...
The thrombopoietin receptor agonists (TPO-RAs) romiplostim, eltrombopag, avatrombopag, and lusutrombopag carry unique US Food and Drug Administration (US FDA)- and European Medicines Agency (EMA)-approved indications and may be used to increase platelet counts in a variety of conditions. Current indications for available TPO-RAs include treatment of chronic immune thrombocytopenia (ITP) in cases of insufficient response to prior treatment (avatrombopag, eltrombopag, romiplostim), management of t...
Abstract null null The management of immune thrombocytopenic purpura (ITP) involves several lines of therapy such as corticosteroids and intravenous immunoglobulin. With the emergence of novel therapies such as thrombopoietin receptor agonists (TPO-RAs), there has been a shift in treatment modalities. Eltrombopag and romiplostim have proven to be effective in the management of ITP through clinical studies, but their safety in pregnancy remains uncertain. The purpose of the study is to review the...
#1Franco RadaelliH-Index: 33
#2Cesare HassanH-Index: 92
Last. Lorenzo Fuccio (UNIBO: University of Bologna)H-Index: 10
view all 5 authors...